Who are Simdax's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Simdax, Sutent, Sunitinib Malate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levosimendan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Simdax — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Simdax (LEVOSIMENDAN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Moderate Risk QT Prolonging Agents. Area: Cardiovascular.

phase 3 Moderate Risk QT Prolonging Agents Troponin C, slow skeletal and cardiac muscles Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Simdax (LEVOSIMENDAN). Simdax works by binding to troponin C, increasing calcium sensitivity in cardiac muscle cells, allowing for improved heart function without increasing oxygen demand.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Simdax TARGET	LEVOSIMENDAN		phase 3	Moderate Risk QT Prolonging Agents	Troponin C, slow skeletal and cardiac muscles
Simdax	Simdax	Yooyoung Pharmaceutical Co., Ltd.	phase 3		ATP-sensitive inward rectifier potassium channel 8, ATP-sensitive inward rectifier potassium channel 11, Troponin C, slow skeletal and cardiac muscles
Sutent	sunitinib	Pfizer	marketed	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
Sunitinib Malate	sunitinib-malate	Pfizer	marketed	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Moderate Risk QT Prolonging Agents class)

Pfizer · 2 drugs in this class
· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simdax — Competitive Intelligence Brief. https://druglandscape.com/ci/levosimendan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing